AptarGroup, Inc. (ATR)
NYSE:ATR
Want to see ATR full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.36Last Year’s EPS
1.66Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: solid cash generation, product wins, meaningful pharma pipeline progress and targeted investments underpin medium-to-long-term growth. However, near-term headwinds—most notably a ~$65 million emergency medicine destock, margin compression across segments (Beauty and Closures), operational disruptions, and rising input costs—create tangible short-term pressure on profitability. Management expects sequential improvement and has provided a Q2 EPS range and full-year investment outlook, but near-term metrics reflect a mix of positive commercial momentum and notable operational and cost challenges.Company Guidance
Reported Sales Growth
Reported sales increased 11% year-over-year while core sales (adjusted for currency and acquisitions) were flat versus the prior year, indicating currency-driven reported growth and underlying stable demand.
Adjusted EBITDA and Cash Generation
Adjusted EBITDA was $189 million, up 3% year-over-year, with adjusted EBITDA margin of 19.2%. Free cash flow more than doubled to $53 million (cash from operations $119M less capex $65M).
Strong Shareholder Returns and Balance Sheet
Returned $131 million to shareholders in the quarter through $100 million of share repurchases and $31 million in dividends. Cash balance of $223 million, net debt of $1.1 billion and leverage ratio of 1.43, supporting continued optionality.
Pharma Growth Drivers and Pipeline Progress
Pharma showed strength in several areas: Injectables core sales grew 20%, Consumer Healthcare up 4%, and the pharma pipeline advanced with multiple Phase 2 intranasal programs and regulatory/approval milestones (e.g., NEFFY U.S. label change removing age criteria, approvals in Canada and UAE).
Product Launches and Commercial Wins in Beauty & Consumer
Multiple commercial placements and launches: Dior Addict using a prestige perfume pump, Guerlain Aqua Allegoria using spray tech for alcohol-free formulas, Clarins Double Serum Foundation using dual dispensing, Clorox daily air spray actuator, and new inverted lidless closures deployed in pet care—demonstrating product-market traction.
Pharma Product Approvals and Generic Win
Notable regulatory items: NEFFY label expansion in U.S., Health Canada and UAE approvals; Cipla received U.S. FDA approval for an AB-rated generic Ventolin using Aptar’s MDI valve—validating aperture and valve technology across originator and generic markets.
Operational Investment and Outlook
Company guided Q2 adjusted EPS of $1.32 to $1.40 and full-year capex of $260–$280 million with D&A $310–$320 million, signaling continued investment for growth and expecting sequential margin improvements as operational issues are addressed.
Risk Management Actions
Proactive actions: increasing raw material safety stocks, passing input-cost increases through to customers where contractually supported, and active supply-chain monitoring in response to Middle East conflict-driven cost pressures.
ATR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ATR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $123.19 | $118.55 | -3.77% |
Feb 05, 2026 | $123.49 | $133.78 | +8.33% |
Oct 30, 2025 | $123.39 | $115.11 | -6.71% |
Jul 31, 2025 | $155.34 | $139.73 | -10.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AptarGroup, Inc. (ATR) report earnings?
AptarGroup, Inc. (ATR) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is AptarGroup, Inc. (ATR) earnings time?
AptarGroup, Inc. (ATR) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ATR EPS forecast?
ATR EPS forecast for the fiscal quarter 2026 (Q2) is 1.36.